Literature DB >> 22999938

TET1 suppresses cancer invasion by activating the tissue inhibitors of metalloproteinases.

Chih-Hung Hsu1, Kai-Lin Peng, Ming-Lun Kang, Yi-Ren Chen, Yu-Chih Yang, Chin-Hsien Tsai, Chi-Shen Chu, Yung-Ming Jeng, Yen-Ting Chen, Feng-Mao Lin, Hsien-Da Huang, Yun-Yuh Lu, Yu-Ching Teng, Shinn-Tsuen Lin, Ruo-Kai Lin, Fan-Mei Tang, Sung-Bau Lee, Huan Ming Hsu, Jyh-Cherng Yu, Pei-Wen Hsiao, Li-Jung Juan.   

Abstract

Tumor suppressor gene silencing through cytosine methylation contributes to cancer formation. Whether DNA demethylation enzymes counteract this oncogenic effect is unknown. Here, we show that TET1, a dioxygenase involved in cytosine demethylation, is downregulated in prostate and breast cancer tissues. TET1 depletion facilitates cell invasion, tumor growth, and cancer metastasis in prostate xenograft models and correlates with poor survival rates in breast cancer patients. Consistently, enforced expression of TET1 reduces cell invasion and breast xenograft tumor formation. Mechanistically, TET1 suppresses cell invasion through its dioxygenase and DNA binding activities. Furthermore, TET1 maintains the expression of tissue inhibitors of metalloproteinase (TIMP) family proteins 2 and 3 by inhibiting their DNA methylation. Concurrent low expression of TET1 and TIMP2 or TIMP3 correlates with advanced node status in clinical samples. Together, these results illustrate a mechanism by which TET1 suppresses tumor development and invasion partly through downregulation of critical gene methylation.
Copyright © 2012 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22999938     DOI: 10.1016/j.celrep.2012.08.030

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  143 in total

1.  Clinical analysis of NSCLC patients reveals lack of association between EGFR mutation and TET1 downregulation.

Authors:  J-I Lai; Y-C Lai; Y-C Chen; N-K Wang; J-N Pan; W-S Wang; S-C Chang
Journal:  Cancer Gene Ther       Date:  2017-08-04       Impact factor: 5.987

2.  TET1 is a tumour suppressor that inhibits colon cancer growth by derepressing inhibitors of the WNT pathway.

Authors:  F Neri; D Dettori; D Incarnato; A Krepelova; S Rapelli; M Maldotti; C Parlato; P Paliogiannis; S Oliviero
Journal:  Oncogene       Date:  2014-11-03       Impact factor: 9.867

3.  Negative feedback of miR-29 family TET1 involves in hepatocellular cancer.

Authors:  Li Li Lin; Wei Wang; ZhaoYang Hu; Li Wen Wang; Jing Chang; HanGuang Qian
Journal:  Med Oncol       Date:  2014-11-04       Impact factor: 3.064

4.  Transitions from mono- to co- to tri-culture uniquely affect gene expression in breast cancer, stromal, and immune compartments.

Authors:  Mary C Regier; Lindsey J Maccoux; Emma M Weinberger; Keil J Regehr; Scott M Berry; David J Beebe; Elaine T Alarid
Journal:  Biomed Microdevices       Date:  2016-08       Impact factor: 2.838

5.  Re-expression of Selected Epigenetically Silenced Candidate Tumor Suppressor Genes in Cervical Cancer by TET2-directed Demethylation.

Authors:  Christian Huisman; Monique G P van der Wijst; Matthijs Schokker; Pilar Blancafort; Martijn M Terpstra; Klaas Kok; Ate G J van der Zee; Ed Schuuring; G Bea A Wisman; Marianne G Rots
Journal:  Mol Ther       Date:  2015-12-21       Impact factor: 11.454

Review 6.  TET family proteins: new players in gliomas.

Authors:  Er-Bao Bian; Gang Zong; Yong-Sheng Xie; Xiao-Ming Meng; Cheng Huang; Jun Li; Bing Zhao
Journal:  J Neurooncol       Date:  2014-01-07       Impact factor: 4.130

Review 7.  The TET enzymes.

Authors:  Peppi Koivunen; Tuomas Laukka
Journal:  Cell Mol Life Sci       Date:  2017-11-28       Impact factor: 9.261

8.  miR-29b is an indicator of prognosis in breast cancer patients.

Authors:  Yoshiaki Shinden; Tomohiro Iguchi; Sayuri Akiyoshi; Hiroki Ueo; Masami Ueda; Hidenari Hirata; Shotaro Sakimura; Ryutaro Uchi; Yuki Takano; Hidetoshi Eguchi; Keishi Sugimachi; Yuko Kijima; Shoji Natsugoe; Koshi Mimori
Journal:  Mol Clin Oncol       Date:  2015-05-12

9.  An extensive network of TET2-targeting MicroRNAs regulates malignant hematopoiesis.

Authors:  Jijun Cheng; Shangqin Guo; Suning Chen; Stephen J Mastriano; Chaochun Liu; Ana C D'Alessio; Eriona Hysolli; Yanwen Guo; Hong Yao; Cynthia M Megyola; Dan Li; Jun Liu; Wen Pan; Christine A Roden; Xiao-Ling Zhou; Kartoosh Heydari; Jianjun Chen; In-Hyun Park; Ye Ding; Yi Zhang; Jun Lu
Journal:  Cell Rep       Date:  2013-10-10       Impact factor: 9.423

10.  Expression of TET and 5-HmC in Trophoblast Villi of Women with Normal Pregnancy and with Early Pregnancy Loss.

Authors:  Ai-Hua Wu; Dong-Yu Yang; Yu-Dong Liu; Xin Chen; Xu-Long Chen; Shan Lu; Shi-Ling Chen
Journal:  Curr Med Sci       Date:  2018-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.